# Illumina, Inc.: Form 10-Q for the period ended Jun 28, 2026

- Company: [Illumina, Inc.](/companies/ilmn.md) (CIK 1110803)
- Form: 10-Q
- Filed: 2026-07-31
- Accepted by EDGAR: Jul 31, 2026, 17:05 ET
- Period: 2026-06-28
- Accession: 0001110803-26-000160
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-06-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-03-30 to 2026-06-28 | $1.16bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2025-12-29 to 2026-06-28 | $2.25bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2026-03-30 to 2026-06-28 | $389.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2025-12-29 to 2026-06-28 | $760.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2026-03-30 to 2026-06-28 | $770.0m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2025-12-29 to 2026-06-28 | $1.49bn | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-03-30 to 2026-06-28 | $252.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2025-12-29 to 2026-06-28 | $492.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2026-03-30 to 2026-06-28 | $273.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2025-12-29 to 2026-06-28 | $545.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2026-03-30 to 2026-06-28 | $245.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-12-29 to 2026-06-28 | $454.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2026-03-30 to 2026-06-28 | $24.0m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months, 2025-12-29 to 2026-06-28 | $47.0m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2026-03-30 to 2026-06-28 | $53.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-12-29 to 2026-06-28 | $77.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-03-30 to 2026-06-28 | $207.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-12-29 to 2026-06-28 | $340.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-03-30 to 2026-06-28 | $1.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2025-12-29 to 2026-06-28 | $2.22 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-03-30 to 2026-06-28 | $1.37 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2025-12-29 to 2026-06-28 | $2.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-03-30 to 2026-06-28 | 153,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2025-12-29 to 2026-06-28 | 154,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2025-12-29 to 2026-06-28 | $490.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2025-12-29 to 2026-06-28 | $78.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2025-12-29 to 2026-06-28 | $370.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Current assets | at 2026-06-28 | $2.83bn | us-gaap:AssetsCurrent |
| Total assets | at 2026-06-28 | $6.65bn | us-gaap:Assets |
| Current liabilities | at 2026-06-28 | $1.58bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2026-06-28 | $2.84bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm

Filed Jul 31, 2026.
Source: SEC EDGAR, the filing index for accession 0001110803-26-000160. Last ingested by Listed: Nov 14, 2026, 13:59 ET. No prices; not investment advice.
